pomalidomide has been researched along with Myeloproliferative Disorders in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Ali, HK; Barkas, N; Barosi, G; Buck, G; Chowdhury, O; Devos, T; Gale, RP; Gisslinger, H; Hamblin, A; Jiang, Q; Kiladjian, JJ; McMullin, MF; Mead, AJ; Mesa, R; O'Sullivan, J; Passamonti, F; Ribrag, V; Schiller, G; Tefferi, A; Vannucchi, AM; Wang, G; Zhong, J; Zhou, D | 1 |
| Cervantes, F; Gale, RP; Hudgens, S; Khan, ZM; Mesa, R; Passamonti, F; Rivera, C; Tefferi, A; Tencer, T; Verstovsek, S | 1 |
| Al-Ali, HK; Barosi, G; Devos, T; Gale, RP; Gisslinger, H; Jiang, Q; Kiladjian, JJ; McMullin, MF; Mesa, R; Passamonti, F; Reiser, D; Ribrag, V; Schiller, G; Tefferi, A; Vannucchi, AM; Zhong, J; Zhou, D | 1 |
| Benner, A; Blau, IW; Döhner, H; Döhner, K; Gattermann, N; Grießhammer, M; Hebart, H; Heidel, FH; Hochhaus, A; Jost, E; Kreipe, H; Platzbecker, U; Reiter, A; Schafhausen, P; Schlenk, RF; Stegelmann, F; Teleanu, V; Verbeek, W; Waller, C; Werner, M | 1 |
| Abdel-Wahab, O; Barbui, T; Barosi, G; Bernard, OA; Bhalla, K; Cazzola, M; Crispino, JD; Finazzi, G; Gisslinger, H; Gotlib, J; Guglielmelli, P; Gupta, V; Hoffman, R; Kiladjian, JJ; Kralovics, R; Mughal, T; Noel, P; Odenike, O; Pardanani, A; Tefferi, A; Thiele, J; Van Etten, RA; Vannucchi, AM | 1 |
| Santos, FP; Verstovsek, S | 1 |
1 review(s) available for pomalidomide and Myeloproliferative Disorders
| Article | Year |
|---|---|
Breakthroughs in myeloproliferative neoplasms.
Topics: Animals; Everolimus; Humans; Immunologic Factors; Janus Kinase 2; Myeloproliferative Disorders; Nitriles; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Signal Transduction; Sirolimus; Thalidomide | 2012 |
3 trial(s) available for pomalidomide and Myeloproliferative Disorders
| Article | Year |
|---|---|
Use of the Functional Assessment of Cancer Therapy--anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia.
Topics: Anemia; Bayes Theorem; Double-Blind Method; Female; Glucocorticoids; Humans; Male; Myeloproliferative Disorders; Neoplasms; Prednisone; Primary Myelofibrosis; Quality of Life; Thalidomide; Treatment Outcome | 2014 |
A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Erythrocyte Transfusion; Female; Humans; Immunologic Factors; Male; Middle Aged; Myeloproliferative Disorders; Phenotype; Primary Myelofibrosis; Thalidomide; Treatment Outcome; Workflow | 2017 |
Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis.
Topics: Aged; Aged, 80 and over; Alleles; Biomarkers; Chromosome Banding; Female; Humans; Immunologic Factors; Male; Middle Aged; Mutation; Myeloproliferative Disorders; Phenotype; Prednisolone; Primary Myelofibrosis; Thalidomide; Treatment Outcome | 2017 |
2 other study(ies) available for pomalidomide and Myeloproliferative Disorders
| Article | Year |
|---|---|
Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide.
Topics: Disease Management; Disease Susceptibility; Erythrocyte Transfusion; Humans; Mutation; Myeloproliferative Disorders; Primary Myelofibrosis; Spliceosomes; Thalidomide; Treatment Outcome | 2021 |
Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH Symposium.
Topics: Clinical Trials as Topic; Disease Progression; DNA Methylation; DNA, Neoplasm; Drugs, Investigational; Genes, Neoplasm; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Histone Deacetylase Inhibitors; Humans; Inflammation; Interferon alpha-2; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Multicenter Studies as Topic; Myeloproliferative Disorders; Neoplasm Proteins; Polyethylene Glycols; Prognosis; Recombinant Proteins; Thalidomide; Treatment Outcome | 2012 |